De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Atara Biotherapeutics Toekomstige groei
Future criteriumcontroles 1/6
De verwachting is dat Atara Biotherapeutics de winst en omzet met respectievelijk 47.9% en 17.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 24.2% per jaar.
Belangrijke informatie
47.9%
Groei van de winst
24.2%
Groei van de winst per aandeel
Biotechs winstgroei | 28.7% |
Inkomstengroei | 17.8% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Good |
Laatst bijgewerkt | 21 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Sep 06Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Jul 21Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
Jul 03New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
May 14Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive
May 11Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Feb 06Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely
Oct 17Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive
May 18Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Feb 13Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%
Nov 22EMA panel backs approval of Atara's Ebvallo for transplant complication
Oct 14Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre
Sep 28Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline
Aug 17Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 103 | -67 | -115 | -60 | 4 |
12/31/2025 | 94 | -98 | -22 | -39 | 6 |
12/31/2024 | 103 | -91 | -25 | -6 | 6 |
6/30/2024 | 62 | -181 | -142 | -142 | N/A |
3/31/2024 | 35 | -233 | -185 | -184 | N/A |
12/31/2023 | 9 | -276 | -194 | -193 | N/A |
9/30/2023 | 5 | -290 | -201 | -199 | N/A |
6/30/2023 | 7 | -305 | -214 | -213 | N/A |
3/31/2023 | 57 | -215 | -226 | -224 | N/A |
12/31/2022 | 64 | -228 | -275 | -270 | N/A |
9/30/2022 | 71 | -247 | -254 | -248 | N/A |
6/30/2022 | 72 | -248 | -252 | -242 | N/A |
3/31/2022 | 24 | -350 | -250 | -239 | N/A |
12/31/2021 | 20 | -340 | -231 | -221 | N/A |
9/30/2021 | 13 | -328 | -199 | -190 | N/A |
6/30/2021 | 7 | -318 | -190 | -184 | N/A |
3/31/2021 | 4 | -311 | -185 | -179 | N/A |
12/31/2020 | N/A | -307 | -185 | -181 | N/A |
9/30/2020 | N/A | -304 | -242 | -235 | N/A |
6/30/2020 | N/A | -301 | -242 | -235 | N/A |
3/31/2020 | N/A | -298 | -239 | -232 | N/A |
12/31/2019 | N/A | -291 | -241 | -236 | N/A |
9/30/2019 | N/A | -292 | -242 | -234 | N/A |
6/30/2019 | N/A | -279 | -241 | -230 | N/A |
3/31/2019 | N/A | -256 | -232 | -215 | N/A |
12/31/2018 | N/A | -231 | -216 | -180 | N/A |
9/30/2018 | N/A | -186 | -189 | -147 | N/A |
6/30/2018 | N/A | -159 | -163 | -119 | N/A |
3/31/2018 | N/A | -135 | N/A | -100 | N/A |
12/31/2017 | N/A | -119 | N/A | -88 | N/A |
9/30/2017 | N/A | -102 | N/A | -84 | N/A |
6/30/2017 | N/A | -97 | N/A | -79 | N/A |
3/31/2017 | N/A | -88 | N/A | -70 | N/A |
12/31/2016 | N/A | -79 | N/A | -60 | N/A |
9/30/2016 | N/A | -82 | N/A | -50 | N/A |
6/30/2016 | N/A | -69 | N/A | -48 | N/A |
3/31/2016 | N/A | -65 | N/A | -43 | N/A |
12/31/2015 | N/A | -57 | N/A | -37 | N/A |
9/30/2015 | N/A | -46 | N/A | -31 | N/A |
6/30/2015 | N/A | -41 | N/A | -22 | N/A |
3/31/2015 | N/A | -30 | N/A | -20 | N/A |
12/31/2014 | N/A | -28 | N/A | -17 | N/A |
9/30/2014 | N/A | -21 | N/A | -14 | N/A |
6/30/2014 | N/A | -18 | N/A | -12 | N/A |
3/31/2014 | N/A | -15 | N/A | -8 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat ATRA de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat ATRA de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat ATRA de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van ATRA ( 17.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van ATRA ( 17.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ATRA naar verwachting over 3 jaar hoog zal zijn